Formulation and Evaluation of Amlodipine Fast Dissolving Tablets

Fast dissolving tablet is a new era for successful development of controlled release formulation along with various features to provide successful drug delivery. In the present study, an attempt was made to design and evaluate fast dissolving tablets of Amlodipine besylate, which is used commonly for the treatment of angina pectoris. The tablets were prepared by direct compression method followed by sublimation method using super disintegrants sodium starch glycolate, crosspovidone and croscarmellose sodium. The prepared powder blends were evaluated for preformulation parameters. The tablets were evaluated for thickness, hardness, weight variation, drug content uniformity, friability and in vitro drug release studies. In vitro drug release studies were performed by using USP type II apparatus paddle method at 50 rpm in 900 ml of 0.1N HCl as dissolution medium for 30 minutes at 37±0.5°C. The formulation F9 containing Croscarmellose sodium 7 showed better disintegration and dissolution up to 30 minutes. Hence, formulation F9 was considered as optimized formulation which showed the best drug release profile up to 30 minutes. The results of mathematical model fitting of data obtained indicated that, the best fit model in all the cases the release was found to be by diffusion and fickian release. The results of FTIR analysis showed that there was no physical and chemical interaction between drug and other excipients. The study indicates that the fast dissolving tablets of Amlodipine besylate can effectively reduce the adverse effects and frequency of administration of the drug. Aparna. P | Dr. Subash Chandran M. P | Remya S B "Formulation and Evaluation of Amlodipine Fast Dissolving Tablets" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-1 , December 2019, URL: https://www.ijtsrd.com/papers/ijtsrd29563.pdf Paper URL: https://www.ijtsrd.com/pharmacy/pharmaceutics/29563/formulation-and-evaluation-of-amlodipine-fast-dissolving-tablets/aparna-p